Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S Presents at Morgan Stanley 18th Annual Global Healthcare Conference, Sep-14-2020 10:30 AM Transcript

Sep 14, 2020 / 02:30PM GMT
Release Date Price: kr224 (+3.32%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Hello. Welcome you all again to the -- to another session of the Morgan Stanley 18th Annual Global Healthcare Conference. I'm one of the biotech analysts here. My name is David Lebowitz. Before we get started, I just need to go through the requisite disclosures.

Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, disconnect and reach out separately. For important disclosures, please see Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, in this session, I have from Zealand Pharmaceuticals, CEO, Emmanuel Dulac; and CFO, Matt Dallas.

Zealand is a development stage biotechnology company focusing on developing peptide-based medicines. I guess if you could start

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot